CAS NO: | 2479306-60-8 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | CDK9-IN-19 is a highly potent and selectiveCDK9inhibitor with anIC50value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML)[1]. | ||||||||||||||||||||||||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||||||||||||||||||||||||
体外研究 (In Vitro) | CDK9-IN-19 (compound 30i) has antiproliferative activity against a panel of human tumor cell lines with IC50ranks of 0.08~0.64 μM (for example: Hep G2, HCT-116, SW620, A549, MV-4-11, et al.)[1]. Western Blot Analysis[1]
| ||||||||||||||||||||||||||||||||||||||
体内研究 (In Vivo) | CDK9-IN-19 (10, 20 or 40 mg/kg; IV, for 32 days) significantly suppresses the tumour progression in MV4-11 xenograft model[1].
| ||||||||||||||||||||||||||||||||||||||
分子量 | 508.47 | ||||||||||||||||||||||||||||||||||||||
Formula | C26H22F2N4O5 | ||||||||||||||||||||||||||||||||||||||
CAS 号 | 2479306-60-8 | ||||||||||||||||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |